Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.

To the Editor, Sunitinib malate (SU11248) is an orally administered, small-molecule, multiple receptor tyrosine kinase (RTK) inhibitor that targets vasoactive endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptors and stem cell factor receptors [1]. It has been licensed for the treatment of advanced renal cell carcinoma… CONTINUE READING